Lack of effect of supplementation with essential fatty acids on bone mineral density in healthy pre- and postmenopausal women: two randomized controlled trials of Efacal v. calcium alone.

Randomized controlled trials of the effects of the dietary supplement Efacal (Scotia Pharmaceuticals Plc, Guildford, Surrey, UK) v. Ca only on total body bone mineral density (BMD) and markers of bone turnover were conducted in healthy pre- and postmenopausal women separately. Total daily dose for 12 months for the Efacal groups was: Ca 1.0 g, evening primrose oil 4.0 g and marine fish oil 440 mg; and for the control groups was: Ca 1.0 g. Reported compliance was better than 90% in both age groups. For the forty-three premenopausal women (age range 25-40 years), initial mean total body BMD values were similar for Efacal and control groups and both groups showed highly significant mean increases of about 1%; however, there were no significant between-group differences for the changes in BMD or markers of bone turnover. For the forty-two postmenopausal women (age range 50-65 years), initial mean total body BMD values were again well-matched across treatment groups. Both Efacal and control groups showed highly significant decreases in total body BMD of about 1%, but again there were no significant between-group differences in total body BMD or markers of bone turnover. Possible confounding variables such as initial total body BMD were explored but had no effect on the outcome in either age group. Nail quality improved in both age groups and in both Efacal and control groups. Again, there was no significant difference between treatment groups. No evidence was found to support a beneficial effect of Efacal on BMD in these women.

Pre- and postmenopausal women have different bone mineral density responses to the same high-impact exercise.

The effects of a vertical jumping exercise regime on bone mineral density (BMD) have been assessed using randomized controlled trials in both pre- and postmenopausal women, the latter stratified for hormone replacement therapy (HRT). Women were screened for contraindications or medication likely to influence bone. The premenopausal women were at least 12 months postpartum and not lactating; the postmenopausal women had been stable on, or off, HRT for the previous 12 months and throughout the study. BMD was measured blind using dual-energy X-ray absorptiometry at the spine (L2-L4) and the proximal femur. The exercise consisted of 50 vertical jumps on 6 days/week of mean height 8.5 cm, which produced mean ground reactions of 3.0 times body weight in the young women and 4.0 times in the older women. In the premenopausal women, the exercise resulted in a significant increase of 2.8% in femoral BMD after 5 months (p < 0.001, n = 31). This change was significantly greater (p < 0.05) than that found in the control group (n = 26). In the postmenopausal women, there was no significant difference between the exercise and control groups after 12 months (total n = 123) nor after 18 months (total n = 38). HRT status did not affect this outcome, at least up to 12 months. It appears that premenopausal women respond positively to this brief high-impact exercise but postmenopausal women do not.